NBTX Stock Analysis: Nanobiotix | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.087m USD | 12M Return: 710% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.04M
Warnings
Tailwinds
Seasonality
Nanobiotix S.A. (NBTX) is a French clinical-stage biotechnology firm specializing in nanomedicine for oncology. The company’s core technology utilizes NBTXR3, a radioenhancer composed of hafnium oxide nanoparticles designed to increase the dose of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. This physical mechanism of action distinguishes it from traditional systemic drug therapies that rely on chemical interactions.
The company targets a broad range of solid tumors, including head and neck, liver, and lung cancers. To facilitate global distribution, Nanobiotix employs a regional licensing model, evidenced by its partnership with LianBio to develop and commercialize its lead candidate across key Asian markets. In the biotechnology sector, such partnerships are critical for clinical-stage firms to offset high R&D costs and navigate complex regulatory environments in foreign jurisdictions.
Investors looking for deeper technical analysis and valuation metrics should consult ValueRay for further data. Researching the specific clinical trial phases for each targeted indication will provide a clearer picture of the companys path to potential commercialization.
- NBTXR3 clinical trial data readouts drive investor sentiment and valuation
- Janssen partnership milestones and royalty payments provide critical non-dilutive funding
- Regulatory approval timelines for head and neck cancer impact market entry
- Global expansion through LianBio partnership determines penetration in Asian markets
- Cash runway and future equity financing activities influence long-term capital structure
| Net Income: -24.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA 64.79 > 1.0 |
| NWC/Revenue: 17.69% < 20% (prev -35.20%; Δ 52.89% < -1%) |
| CFO/TA -0.49 > 3% & CFO -33.4m > Net Income -24.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.8m) vs 12m ago 1.48% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 43.86% > 50% (prev -10.66%; Δ 54.52% > 0%) |
| Interest Coverage Ratio: -1.30 > 6 (EBIT TTM -13.6m / Interest Expense TTM 10.4m) |
| A: 0.08 (Total Current Assets 62.8m - Total Current Liabilities 57.5m) / Total Assets 67.8m |
| B: -0.35 (Retained Earnings -24.0m / Total Assets 67.8m) |
| C: -0.20 (EBIT TTM -13.6m / Avg Total Assets 67.6m) |
| D: -0.55 (Book Value of Equity -84.5m / Total Liabilities 152.2m) |
| Altman-Z'' = -2.58 = D |
As of July 08, 2026, the stock is trading at USD 38.80 with a total of 108,271 shares traded. Over the past week, the price has changed by +7.90%, over one month by +8.14%, over three months by +28.73% and over the past year by +710.02%.
Current recommended Stop Loss: 32.10 (which is 17.3% or 2.4 ATR below the current price).
Nanobiotix has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy NBTX.
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 43.6 | 12.4% |
Market Cap EUR = 1.83b (2.09b USD * 0.8764 USD.EUR)
P/E Forward = 105.2632
P/S = 59.8341
P/B = 65.0172
Revenue TTM = 29.6m EUR
EBIT TTM = -13.6m EUR
EBITDA TTM = -12.1m EUR
Long Term Debt = 89.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 4.31m EUR (from shortTermDebt, last quarter)
Debt = 98.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 3.10m
Net Debt = 87.6m EUR (calculated: Debt 98.4m - CCE 10.8m)
Enterprise Value = 1.92b EUR (1.83b + Debt 98.4m - CCE 10.8m)
Interest Coverage Ratio = -1.30 (Ebit TTM -13.6m / Interest Expense TTM 10.4m)
EV/FCF = -98.44x (Enterprise Value 1.92b / FCF TTM -19.5m)
FCF Yield = -1.02% (FCF TTM -19.5m / Enterprise Value 1.92b)
FCF Margin = -65.69% (FCF TTM -19.5m / Revenue TTM 29.6m)
Net Margin = -80.83% (Net Income TTM -24.0m / Revenue TTM 29.6m)
Gross Margin = unknown ((Revenue TTM 29.6m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 28.29 (Enterprise Value 1.92b / Total Assets 67.8m)
Interest Expense / Debt = 10.56% (Interest Expense 10.4m / Debt 98.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -10.7m (EBIT -13.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.98 (Total Current Assets 62.8m / Total Current Liabilities 64.1m)
Debt / Equity = -1.16 (negative equity) (Debt 98.4m / totalStockholderEquity, last quarter -84.5m)
Debt / EBITDA = -7.26 (negative EBITDA) (Net Debt 87.6m / EBITDA -12.1m)
Debt / FCF = -4.50 (negative FCF - burning cash) (Net Debt 87.6m / FCF TTM -19.5m)
Total Stockholder Equity = -71.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.45% (Net Income -24.0m / Total Assets 67.8m)
RoE = 33.65% (negative equity) (Net Income TTM -24.0m / Total Stockholder Equity -71.2m)
RoCE = -75.73% (EBIT -13.6m / Capital Employed (Equity -71.2m + L.T.Debt 89.1m))
RoIC = -81.92% (negative operating profit) (NOPAT -10.7m / Invested Capital 13.1m)
WACC = 8.86% (E(1.83b)/V(1.93b) * Re(8.89%) + D(98.4m)/V(1.93b) * Rd(10.56%) * (1-Tc(0.21)))
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 15.09%
[DCF] Fair Price = unknown (Cash Flow -19.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.21 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.04 | Chg30d=-41.38% | Revisions=+0% | GrowthEPS=+108.5% | GrowthRev=+34.5%
EPS next Year (2027-12-31): EPS=0.07 | Chg30d=-45.96% | Revisions=+0% | GrowthEPS=+59.0% | GrowthRev=+24.3%
[Analyst] Revisions Ratio: +0% (up=0, down=0)